Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis

TARRYTOWN, N.Y. and PARIS, March 11, 2016 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was sup... BiopharmaceuticalsRegeneron Pharmaceuticals, Sanofi, sarilumab, rheumatoid arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news